Skip to content
★ Sign in to follow
NA
Total declarations
19
Company
1
▲ Purchases (0 ops.)
—
▼ Sales (0 ops.)
—

Latest filing published 05 Oct 2026 for Longeveron Inc., €6,655.

Insider track record

Disclosed buys
0
Disclosed sells
0
Signal history

Nataliya Agafonova: trading record in brief

Nataliya Agafonova is a declared insider of Longeveron Inc., with filings sourced from SEC (Form 4). Between 24 July 2023 and 1 October 2026, the trades on record add up to 19 filings.

Not one of the filings records a straightforward purchase or sale on the market. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.

The newest entry dates from 5 October 2026: a share grant of €6,655, in Longeveron Inc. The median gap between a trade and its publication by SEC (Form 4) is 4 days. Section 16 rules allow two business days to file each Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.

Companies and markets linked to Nataliya Agafonova

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations18 total
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    7,545 USD0SEC
    2,913 shares@ US$2.59Class A Common StockSEC:0001214659-26-012568:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    0SEC
    286,000 shares0Class A Common StockSEC:0001214659-26-010734:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    16,408 USD22SEC
    22,505 shares@ US$0.72910.18% mcap14.6% of flowClass A Common StockSEC:0001214659-26-008252:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    0SEC
    250,000 shares0Class A Common StockSEC:0001214659-26-005618:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    14,722 USD12SEC
    13,145 shares@ US$1.1212.9% of flowClass A Common StockSEC:0001214659-26-004339:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    6,078 USD12SEC
    10,250 shares@ US$0.5935.2% of flowClass A Common StockSEC:0001214659-26-000206:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    8,822 USD12SEC
    11,883 shares@ US$0.74247.6% of flowClass A Common StockSEC:0001214659-25-014619:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    0SEC
    102,000 shares0Class A Common StockSEC:0001214659-25-010575:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    9,512 USD12SEC
    7,431 shares@ US$1.288.2% of flowClass A Common StockSEC:0001214659-25-010060:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    11,349 USD12SEC
    7,566 shares@ US$1.5010.7% of flowClass A Common StockSEC:0001214659-25-005400:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    10,955 USD12SEC
    6,120 shares@ US$1.7910.7% of flowClass A Common StockSEC:0001214659-25-000231:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    9,994 USD12SEC
    5,316 shares@ US$1.889.2% of flowClass A Common StockSEC:0001214659-24-017154:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    0SEC
    175,750 shares0Class A Common StockSEC:0001214659-24-014995:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    872 USD11SEC
    308 shares@ US$2.830.8% of flowClass A Common StockSEC:0001214659-24-008444:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    4,058 USD11SEC
    3,074 shares@ US$1.323.7% of flowCommon StockSEC:0001214659-24-001202:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    7,005 USD12SEC
    3,059 shares@ US$2.296.8% of flowCommon StockSEC:0001214659-23-013142:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    10,352 USD12SEC
    3,081 shares@ US$3.369.6% of flowCommon StockSEC:0001214659-23-011606:0
  • ◆
    Chief Medical OfficerExecutivesLongeveron Inc.
    0SEC
    30,000 shares0Common StockSEC:0001214659-23-010670:0

18 of 18 declarations